AIM ImmunoTech Inc. (AIM)

NYSEAMERICAN: AIM · Real-Time Price · USD
0.210
-0.008 (-3.67%)
Dec 11, 2024, 4:00 PM EST - Market closed
-3.67%
Market Cap 13.39M
Revenue (ttm) 190,000
Net Income (ttm) -23.93M
Shares Out 63.78M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 154,712
Open 0.220
Previous Close 0.218
Day's Range 0.201 - 0.220
52-Week Range 0.160 - 0.620
Beta -0.40
Analysts Strong Buy
Price Target 2.75 (+1,209.52%)
Earnings Date Nov 15, 2024

About AIM

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1966
Employees 28
Stock Exchange NYSEAMERICAN
Ticker Symbol AIM
Full Company Profile

Financial Performance

In 2023, AIM ImmunoTech's revenue was $202,000, an increase of 43.26% compared to the previous year's $141,000. Losses were -$28.96 million, 48.9% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for AIM stock is "Strong Buy." The 12-month stock price forecast is $2.75, which is an increase of 1,209.52% from the latest price.

Price Target
$2.75
(1,209.52% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has grant...

11 minutes ago - GlobeNewsWire

Kellner Group Announces Support from Another Former AIM Senior Executive

NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectivel...

55 minutes ago - GlobeNewsWire

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectivel...

1 day ago - GlobeNewsWire

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recomme...

1 day ago - Business Wire

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) ...

2 days ago - GlobeNewsWire

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here

5 days ago - GlobeNewsWire

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency According to ISS – “ There is no question that for shareholders to have any hope of not losing 100 p...

6 days ago - GlobeNewsWire

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has...

7 days ago - Business Wire

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation highlighting why shareholders should NOT elect the four director candidates ...

10 days ago - Business Wire

AIM ImmunoTech Refutes Activist Group's False and Misleading Claims

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement refuting the false and misleading claims recently made by a group o...

14 days ago - Business Wire

AIM ImmunoTech Announces Cash Conservation Plan

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Compensation Committee of the Company's Board of Directors (the “Board”) has es...

15 days ago - Business Wire

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation in connection with its upcoming 2024 Annual Meeting of Stockholders the (“An...

17 days ago - Business Wire

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer Center's ...

23 days ago - GlobeNewsWire

AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

AIM ImmunoTech Inc. (NYSE:AIM) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Particip...

26 days ago - Seeking Alpha

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space

27 days ago - GlobeNewsWire

Aimia Inc. (AIMFF) Q3 2024 Earnings Call Transcript

Aimia Inc. (OTCPK:AIMFF) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Joe Racanelli - Vice President of Investor Relations Tom Finke - Executive Chairman Steve Leo...

4 weeks ago - Seeking Alpha

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the...

5 weeks ago - GlobeNewsWire

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”) today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange C...

5 weeks ago - Business Wire

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted ...

2 months ago - GlobeNewsWire

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on...

2 months ago - GlobeNewsWire

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and two other...

4 months ago - GlobeNewsWire

AIM ImmunoTech Inc. (AIM) Q2 2024 Earnings Call Transcript

AIM ImmunoTech Inc. (NYSE:AIM) Q2 2024 Earnings Conference Call August 16, 2024 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer, President & Executive Vice Chairman Christophe...

4 months ago - Seeking Alpha

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications

4 months ago - GlobeNewsWire

Aimia Inc. (AIMFF) Q2 2024 Earnings Call Transcript

Aimia Inc. (OTCPK:AIMFF) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Joe Racanelli - Investor Relations Tom Finke - Executive Chairman Steve Leonard - President & ...

4 months ago - Seeking Alpha

AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast

OCALA, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the...

4 months ago - GlobeNewsWire